114 related articles for article (PubMed ID: 32014930)
1. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series.
Gonzalez A; Walker EJ; Van Loon K; Cinar P; Atreya CE
Anticancer Res; 2020 Feb; 40(2):865-871. PubMed ID: 32014930
[TBL] [Abstract][Full Text] [Related]
2. Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.
Besora S; Santos C; Izquierdo C; Martinez-Villacampa MM; Bruna J; Velasco R
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1793-1801. PubMed ID: 29955956
[TBL] [Abstract][Full Text] [Related]
3. Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.
Anon B; Largeau B; Girault A; Chantome A; Caulet M; Perray C; Moussata D; Vandier C; Barin-Le Guellec C; Lecomte T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):149-157. PubMed ID: 29774408
[TBL] [Abstract][Full Text] [Related]
4. Effects of compound porcine cerebroside and ganglioside on neurotoxicity caused by oxaliplatin chemotherapy: preliminary results.
Zhang YL; Wei LY; Yao HW; Jin L; Wang J; Zhang J; Zhao XM; Cai J; Bai ZG; Deng W
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5441-5448. PubMed ID: 31298397
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities: A Longitudinal Study Among Patients With Colorectal Cancer.
Drott J; Fomichov V; Starkhammar H; Börjeson S; Kjellgren K; Berterö C
Cancer Nurs; 2019; 42(6):E40-E48. PubMed ID: 31658096
[TBL] [Abstract][Full Text] [Related]
6. Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care.
Lim KH; Nguyen NN; Qian Y; Williams JL; Lui DD; Bruera E; Yennurajalingam S
J Palliat Med; 2018 Dec; 21(12):1698-1704. PubMed ID: 30260731
[No Abstract] [Full Text] [Related]
7. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
8. Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.
Han CH; Kilfoyle DH; Hill AG; Jameson MB; McKeage MJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1479-1490. PubMed ID: 27539508
[TBL] [Abstract][Full Text] [Related]
9. Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone.
Omoto T; Asaka J; Nihei S; Kudo K
Support Care Cancer; 2023 Mar; 31(4):208. PubMed ID: 36907927
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Ketamine for Rapid Opioid Dose Reduction, Reversal of Opioid-Induced Neurotoxicity, and Pain Control in Terminal Care: Case Report and Literature Review.
Winegarden J; Carr DB; Bradshaw YS
Pain Med; 2016 Apr; 17(4):644-9. PubMed ID: 26234740
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Goldwasser F; Gross-Goupil M; Tigaud JM; Di Palma M; Marceau-Suissa J; Wasserman E; Yovine A; Misset JL; Cvitkovic E
Ann Oncol; 2000 Nov; 11(11):1463-70. PubMed ID: 11142487
[TBL] [Abstract][Full Text] [Related]
13. Effects of analgecine on oxaliplatin-induced neurotoxicity in patients with gastrointestinal cancer.
Liu MY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(10):4465-8. PubMed ID: 26028115
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer.
Drott J; Starkhammar H; Kjellgren K; Berterö C
Oncol Nurs Forum; 2018 Nov; 45(6):690-697. PubMed ID: 30339148
[TBL] [Abstract][Full Text] [Related]
15. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
17. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy.
Bruna J; Velasco R
Neural Regen Res; 2018 May; 13(5):775-778. PubMed ID: 29862996
[TBL] [Abstract][Full Text] [Related]
18. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies.
Yip D; Karapetis C; Strickland AH; Steer C; Holford C; Knight S; Harper P
Ann Oncol; 2003 Jun; 14(6):864-6. PubMed ID: 12796023
[TBL] [Abstract][Full Text] [Related]
20. A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Joseph R; Dasanu CA
J Oncol Pharm Pract; 2014 Oct; 20(5):393-6. PubMed ID: 24103898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
